Lea Menear
Optometrist · Wilmington, DENPI 1003811183
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 181 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Mallinckrodt Hospital Products Inc. at 34.1% of the total. 2025 is the largest year on record at $1,057, 3.3 times the $319 reported in 2019. Among optometrist clinicians in DE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 181 payments — averaging $24.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Hospital Products Inc.$1K
- Bausch & Lomb Americas Inc.$443
- Bausch & Lomb, A Division Of Bausch Health US, LLC$409
- Sun Pharmaceutical Industries Inc.$366
- AbbVie$277
- Tarsus Pharmaceuticals, Inc.$265
- plus $1K from 15 others
What the payments were for
- Food & beverage$4,365100%
- Entertainment$160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Hospital Products Inc. | 49 | $1,492 |
| Bausch & Lomb Americas Inc. | 24 | $443 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 13 | $409 |
| Sun Pharmaceutical Industries Inc. | 14 | $366 |
| AbbVie(2 entities) | 14 | $277 |
| Tarsus Pharmaceuticals, Inc. | 11 | $265 |
| Alcon | 10 | $198 |
| Dompe US, Inc. | 7 | $188 |
| Oyster Point Pharma, Inc. | 9 | $175 |
| Novartis | 6 | $118 |
| Harrow Eye, LLC | 4 | $103 |
| Eyevance Pharmaceuticals LLC | 7 | $91 |
| ANI Pharmaceuticals, Inc. | 4 | $71 |
| Kala Pharmaceuticals, Inc. | 2 | $49 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $27 |
| Rxsight Inc | 1 | $21 |
| Biotissue Holdings Inc. | 1 | $20 |
| Coopervision Inc. | 1 | $19 |
| Eyepoint US, Inc. | 1 | $16 |
| Optos, Inc. | 1 | $16 |
| Amgen | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,381 in reported general payments places this provider in the 95th percentile of 146 optometrist providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 26 | $43,697 |
| MieboPerfluorohexyloctane/Pf | 32 | $26,714 |
| XiidraLifitegrast | 15 | $20,438 |
| VyzultaLatanoprostene Bunod | 17 | $11,690 |
| CequaCyclosporine | 14 | $11,231 |
| LumiganBimatoprost | 27 | $10,990 |
| Loteprednol Etabonate | 39 | $5,930 |
| Travoprost | 11 | $2,544 |
| Prednisolone Acetate | 50 | $2,162 |
| Brimonidine Tartrate | 41 | $1,493 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 23 | $1,250 |
| Latanoprost | 90 | $1,179 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 92 | $880 |
| Doxycycline Hyclate | 31 | $574 |
| ErythromycinErythromycin Base | 53 | $563 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Miebo, Xiidra, Vyzulta | $443 | $58,84264 claims |
| AbbVieRestasis, Lumigan | $277 | $54,68753 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $366 | $11,23114 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $409 | $5,93039 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 146 optometrist providers in Delaware.
Other optometrist in Wilmington
- Jennifer TuranoWilmington$42K
- Laura GoldbergWilmington$17K
- Lorna SimmermanWilmington$4K
- Alissa LongWilmington$4K
- Scott TucciWilmington$3K
- Sarah Nowicki-DuczeminskiWilmington$3K
- Daniel BaruffiWilmington$2K
- Jamie WohlhagenWilmington$2K
- Leanne HeuerWilmington$2K
- Alex QuachWilmington$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.